In an effort to reach and serve Hispanics more effectively, staff members at Wake Research Associates recently completed training and testing through Blaire Borthayre, CEO of Hispanic Marketing Resources
(www.hispanicmarketingresources.com). According to Borthayre, all participants from Wake Research, a clinical research site located in Raleigh, North Carolina, passed the final exam with no errors. The course focuses on improving Hispanic participation in clinical trials through a culturally sensitive approach to the special needs of the foreign born Hispanic. Topics include building trusting relationships in the Hispanic community, avoiding cultural behaviors that offend, working effectively with interpreters, and overcoming common barriers.
Blaire is a Hispanic advocate and cultura lexpert who works with businesses seeking to increase Hispanic clientele. “I do not work with businesses who seek only to have their materials translated into Spanish.” Says Borthayre “ I work only with those who demonstrate a willingness to implement a holistic, culturally appropriate program and the first step is staff training.”
Hispanics make up only 1% of clinical trial participants in trials where ethnic background is identified. While this is often attributed to the language barrier, Borthayre explains the true cause is a lack of understanding about the foreign born Hispanics who experience life in different cultural context than that of the traditional mainstream American. “Motivations and concerns regarding clinical trials are very different for the Hispanic immigrant and those issues are simply not addressed by most clinical sites.” Borthayre is a graduate of the Hispanic Marketing and Communications Program at Florida State University and has been researching Hispanic attitudes and beliefs regarding clinical trials for the past three years. The results of focus groups and surveys were combined to create a training for clinical sites that focuses on an overall change in the traditional recruitment approach.
Borthayre states that Wake Research Associates has impressed her with their commitment to this project. “Dr. Ella Grach, Medical Director at Wake Research made the time to be personally involved in this certification process. Too often clinical research sites delegate the issue of Hispanic recruitment to a staff member and then hope for the best. The most effective programs are those who have support and participation from the top. Leaders have to set the example.” Wake Research Associates is an independent multi-center clinical research site designed to work closely with and meet the needs of the pharmaceutical industry and clinical research organizations (www.wakeresearchassociates.com).
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.